Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) is trading up 5% today with volume reaching over 120k. CNBX has been on a steady climb since earlier in the month and is now sporting a +100% increase since then. The company is riding a CBD deal with a German leader in liquid biopsies. The news is very exciting and traders are reacting.
According to the release, under the Agreement, Cannabics Pharmaceuticals shall be the exclusive global provider of SIMFO’s CTC diagnostics to cancer patients treated with natural cannabinoids. The diagnostics include a count of circulating tumor cells (CTC) and drug sensitivity tests of different cannabinoids (e.g. THC, THCA, CBD and CBDA).
Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) is intent on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics’ vision is to create individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Find out when $CNBX stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
SIMFO has already begun preclinical trials on CBD antitumor activity and drug expansion using Cannabics Pharmaceuticals’ cannabinoid formulations. Dr. Eyal Ballan, the CTO and Co-founder, mentioned that they are privileged to work together with SIMFO’s reputed scientists and physicians. They consider their collaboration will pave the way for effective natural anticancer therapy.
Dr. Ballan said: “We are honored to work hand in hand with SIMFO’s noted scientists and physicians. We believe our collaboration will pave the way for highly effective natural anticancer therapy.”
SIMFO GmbH mark as a R&D facility that has attained medical prominence expertise in tailored medicine. It focuses mainly on the development of state-of-the-art analysis techniques in oncological diagnostics to enhance patient-specific therapy. SIMFO GmbH advances foreign clients and collaborative associates. Blood samples from over 40 nations across the world have now been obtained at the Transfusion Medicine Center.
CNBX’s flagship product is Cannabics SR, a long-acting medical cannabis capsule that shows therapeutic effects as a palliative care therapy for cancer patients.
The Company’s scientific focus is on identifying and harnessing the therapeutic properties of specific natural Cannabinoids. Cannabics’ vision is to create individually tailored therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Owning a market cap of $232.31M, CNBX is continuing to climb the mountain and this development puts them on the path to relevance and legitimacy. The company still needs to stem some top-line losses, but they are a very exciting story in the space and need to be followed. For continuing coverage on shares of $CNBX stock, as well as our other breakout stock picks, sign up for our free newsletter today and get our next hot stock pick!
Disclosure: we hold no position in $CNBX, either long or short, and we have not been compensated for this article.
